Efficacy and Safety of Cagrilintide-Semaglutide Combination vs Semaglutide Alone for Weight Management in East Asian Adults with Overweight/Obesity: REDEFINE 5 Trial

Breakthrough Combination Therapy for Weight Management

The REDEFINE 5 trial demonstrates that co-administered cagrilintide and semaglutide significantly outperforms semaglutide monotherapy for weight reduction in East Asian populations. This dual-hormone approach represents a promising advancement in obesity therapeutics, particularly relevant for Asian populations where lower BMI thresholds often predict metabolic complications. The combination leverages complementary mechanisms: semaglutide (a GLP-1 receptor agonist) reduces appetite via brain receptors and slows gastric emptying, while cagrilintide (an amylin analogue) enhances satiety signals and modulates glucose metabolism.

Rigorous Clinical Trial Design

This multicenter, double-blind, active-controlled phase 3a trial enrolled 331 adults across 22 sites in Japan and Taiwan. Participants met strict criteria: age ≥18 years with either BMI ≥27 kg/m² plus ≥2 obesity-related complications or BMI ≥35 kg/m² plus ≥1 complication, aligning with Japan Society for the Study of Obesity guidelines. Notably, 24% had type 2 diabetes. Participants were randomized 1:1 to receive weekly subcutaneous injections of either cagrilintide-semaglutide fixed-dose combination (2.4 mg each) or semaglutide alone (2.4 mg), with gradual dose escalation over 68 weeks alongside lifestyle intervention. The trial utilized centralized randomization stratified by planned CT scans, baseline BMI ≥35 kg/m², and diabetes status.

Compelling Efficacy Results

At week 68, the cagrilintide-semaglutide group achieved remarkable 18.4% mean weight reduction (SE 0.7%) versus 11.9% (SE 0.7%) with semaglutide monotherapy. This translated to a significant estimated treatment difference of -6.5 percentage points (95% CI: -8.4 to -4.6; p<0.0001). The combination therapy's superiority was consistent across subgroups regardless of diabetes status. The discontinuation rate was slightly higher in the combination group (10% vs 6%), potentially reflecting transient gastrointestinal effects. These results are particularly meaningful for East Asian populations who often develop obesity-related complications at lower BMIs than Western populations.

Safety and Tolerability Profile

Safety analysis revealed comparable adverse event rates between groups: 87% (143/164) in the combination group versus 84% (141/167) in the monotherapy group. Gastrointestinal disorders predominated (53% vs 51%), including nausea, vomiting and diarrhea – consistent with incretin-based therapies. Most events were mild-moderate and diminished over time. One death occurred in the semaglutide group, deemed unrelated to treatment by investigators. The safety profile aligns with global studies, supporting combination therapy’s manageability in clinical practice. No unexpected safety signals emerged in this East Asian cohort.

Clinical Implications and Future Directions

REDEFINE 5 provides robust evidence that cagrilintide-semaglutide combination offers clinically meaningful weight reduction beyond current GLP-1 monotherapies for East Asian populations. The 6.5% additional weight loss could significantly impact obesity-related comorbidities like hypertension, dyslipidemia, and diabetes control. Future research should explore: 1) Long-term sustainability beyond 68 weeks 2) Cardiovascular outcomes 3) Effects on specific complications prevalent in Asians (nonalcoholic fatty liver disease, renal impairment) 4) Potential differential effects in populations with varying diabetes durations. This therapeutic approach may transform obesity management strategies in regions experiencing rapidly rising obesity rates.

Conclusion and Global Relevance

This landmark trial demonstrates that cagrilintide-semaglutide combination therapy delivers superior, clinically significant weight reduction versus semaglutide alone in East Asian adults with overweight/obesity ± type 2 diabetes, with manageable side effects. The 18.4% weight loss approaches the 20% threshold considered ‘disease-modifying’ for obesity. These findings support the combination’s potential as a transformative treatment option in global obesity management, particularly valuable for populations needing greater efficacy than current monotherapies. The results highlight the importance of region-specific clinical validation for obesity therapies.

Funding and Disclosures

This study was funded by Novo Nordisk. The authors reported conflicts of interest including research grants, consulting fees, and speaker honoraria from Novo Nordisk and other pharmaceutical companies. Full trial details available at ClinicalTrials.gov (NCT05813925). The Japanese and Mandarin translations of the abstract are available in Supplementary Materials.